Stockscreener 앱 받기
0.8556
0.36%
-0.0031
시간 외 거래:
.84
-0.0156
-1.82%
전일 마감가:
$0.8587
열려 있는:
$0.8655
하루 거래량:
77,415
Relative Volume:
0.12
시가총액:
$10.14M
수익:
-
순이익/손실:
$-7.51M
주가수익비율:
-0.6482
EPS:
-1.32
순현금흐름:
$-8.02M
1주 성능:
+8.63%
1개월 성능:
-17.73%
6개월 성능:
+1.86%
1년 성능:
-26.87%
1일 변동 폭
$0.8259
$0.8655
1주일 범위
$0.74
$0.869
52주 변동 폭
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
명칭
Hoth Therapeutics Inc
전화
(646)756-2997
주소
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
HOTH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
0.8556 | 10.14M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-10-15 | 개시 | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc 주식(HOTH)의 최신 뉴스
Quarterly Snapshot: Quick and Current Ratios for Hoth Therapeutics Inc (HOTH) - DWinneX
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Hoth secures Japan patent for RNA cancer therapy targeting KIT gene - Investing.com Canada
Hoth secures Japan patent for RNA cancer therapy targeting KIT gene By Investing.com - Investing.com South Africa
Revolutionary RNA Cancer Treatment Gets Japanese Patent: Hoth's KIT Gene Therapy Targets Multiple Cancers - Stock Titan
Hoth Therapeutics (HOTH) Reports Promising Phase 2a Results for Pruritus Treatment | HOTH Stock News - GuruFocus
Hoth Therapeutics reports progress in pruritus treatment trial By Investing.com - Investing.com South Africa
Hoth Therapeutics Announces Positive Initial Data In Phase 2A Clinical Trial - TradingView
Hoth Therapeutics reports progress in pruritus treatment trial - Investing.com
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial - Longview News-Journal
Hoth Therapeutics reports Alzheimer’s drug candidate success By Investing.com - Investing.com Nigeria
Hoth Therapeutics (HOTH) Reports Promising Data for Alzheimer's Candidate HT-ALZ - GuruFocus
Hoth Flat on Hookup with Washington Univ. - Baystreet.ca
Hoth Therapeutics reports Alzheimer’s drug candidate success - Investing.com India
Hoth Therapeutics Plans To Advance HT-ALZ Into Clinical Development - MarketScreener
Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ - Longview News-Journal
Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours - PR Newswire
Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World
Hoth Therapeutics receives USPTO filing receipt for HT-001 patent application - TipRanks
Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage - PR Newswire
Hoth Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Hoth Therapeutics Inc. (HOTH) reports earnings - Quartz
Hoth Therapeutics, Inc. SEC 10-K Report - TradingView
Hoth Therapeutics enhances patent claims, begins toxicity study By Investing.com - Investing.com South Africa
Hoth Therapeutics enhances patent claims, begins toxicity study - Investing.com
Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation - Marketscreener.com
Major Progress: Hoth's Cancer-Fighting Drug Secures Patent Protection and Launches Critical Safety Study - Stock Titan
Hoth Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Hoth Therapeutics (HOTH) Projected to Post Earnings on Thursday - Defense World
Balance Sheet Breakdown: Hoth Therapeutics Inc (HOTH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Hoth Therapeutics announces ‘positive’ results from study of HT-KIT - Yahoo Finance
Hoth reports progress in GIST treatment with HT-KIT By Investing.com - Investing.com Australia
Hoth reports progress in GIST treatment with HT-KIT - Investing.com India
Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment - PR Newswire
Revolutionary 24-Hour Cancer Treatment Success: Hoth's HT-KIT Destroys GIST Tumors in Breakthrough Study - Stock Titan
Short Interest in Hoth Therapeutics, Inc. (NASDAQ:HOTH) Decreases By 24.8% - Defense World
Hoth Therapeutics to submit HT-001 expanded access application By Investing.com - Investing.com Australia
Hoth Therapeutics Announces Plans To Submit Expanded Access Application For Ht-001 To Support Cancer Patients In Need - Marketscreener.com
Hoth Dips on Drug Application - Baystreet.ca
Hoth Therapeutics to submit Expanded Access application for HT-001 - TipRanks
Hoth Therapeutics to submit HT-001 expanded access application - Investing.com India
Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need - PR Newswire
Hoth Therapeutics reports HT-001 cream success in skin toxicity By Investing.com - Investing.com South Africa
Hoth Therapeutics reports HT-001 cream success in skin toxicity - Investing.com India
Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate - TipRanks
Hoth Therapeutics Inc (HOTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):